TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15657024

Group type: EXPERIMENTAL
Intervention: Choice between 4 active alternatives or 4 sedentary alternatives (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Least valued sedentary activity (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Most valued sedentary activity (Group 3)
Number of subjects: 30
Study: 11579250

Group type: EXPERIMENTAL
Intervention: Disclosure to a partner
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Cohabiting, low wage employment, previous disclosure to a female relative, ever-use of modern contraceptive method
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Fewer than six lifetime sexual partners, knowing someone with HIV/AIDS
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Knowing more than two individuals with HIV/AIDS, full economic dependency on partner, high levels of social support, prior attendance at a support group meeting
Number of subjects: 1078
Study: 9649160

Group type: EXPERIMENTAL
Intervention: MVP (mitomycin‐C 6 mg m(‐2) on day 1, vindesine 3 mg m(‐2) on days 1 and 15, and cisplatin 80 mg m(‐2) on day 1 every 28 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PIN (cisplatin 80 mg m(‐2) day 1, ifosfamide 3 g m(‐2) day 1 and vinorelbine 25 mg m(‐2) day 1 and 8 every 21 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CaN (carboplatin 350 mg m(‐2) day 1 and vinorelbine 25 mg m(‐2) days 1 and 8 every 28 days)
Number of subjects: 140
Study: 7913675

Group type: COMPARATOR
Intervention: Active control trials with a specified region of therapeutic equivalence for two responses related to efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivariate group sequential design
Number of subjects: 0
Study: 2688238

Group type: EXPERIMENTAL
Intervention: Porcine insulin (PI)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Human insulin (HI)
Number of subjects: 8
Study: 1089678

Group type: EXPERIMENTAL
Intervention: 10 μg GnRH/m2 iv in children
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1, 10, 25, and 100 μg GnRH/m2 iv in adults
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GnRH iv at 10 μg/m2 in children
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GnRH iv in adults
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GnRH iv in children and adults
Number of subjects: 29
Study: 31314206

Group type: EXPERIMENTAL
Intervention: Sweetened beverages consumption (≥500 ml daily)
Number of subjects: 931
Study: 27542378

Group type: EXPERIMENTAL
Intervention: Multimedia self-management intervention for lung surgery preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26992066

Group type: EXPERIMENTAL
Intervention: A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: PROWESS‐SHOCK
Number of subjects: 2129
Study: 24835760

Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD OCT)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Time-domain optical coherence tomography (TD OCT)
Number of subjects: 384
Study: 21787456

Group type: EXPERIMENTAL
Intervention: Barley porridge with 16 g/100 g fibre content
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Barley porridge with 10 g/100 g fibre content
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference glucose
Number of subjects: 10
Study: 20530281

Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (DP) chemotherapy with concurrent thoracic radiotherapy (TRT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mitomycin, vindesine, and cisplatin (MVP) chemotherapy with concurrent TRT
Number of subjects: 200

Group type: COMPARATOR
Intervention: MVP arm
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: DP arm
Number of subjects: 200
Study: 17949578

Group type: EXPERIMENTAL
Intervention: Ericksonian hypnosis (EH)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham-hypnosis (SH)
Number of subjects: 43
Study: 15613140

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 17
Study: 12039615

Group type: EXPERIMENTAL
Intervention: Psychotropic analgesic nitrous oxide (PAN)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Benzodiazepine (diazepam)
Number of subjects: 23
Study: 10022628

Group type: EXPERIMENTAL
Intervention: Omeprazole-infusion
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ranitidine-infusion
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Omeprazole-injection
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ranitidine-injection
Number of subjects: 34
Study: 7595265

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy consultation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 56
Study: 2260432

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 63
Study: 7411122

Group type: EXPERIMENTAL
Intervention: Lists of six colored Xs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lists of six colored words
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lists of six color names printed in incongruent colors
Number of subjects: 60
Study: 31496045

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study: 30864090

Group type: EXPERIMENTAL
Intervention: Kedo-S rotary files
Number of subjects: 69

Group type: COMPARATOR
Intervention: K-file
Number of subjects: 69

Group type: COMPARATOR
Intervention: H-file
Number of subjects: 69
Study: 28267900

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ledipasvir (LDV) for 12 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ledipasvir (LDV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sofosbuvir (SOF) + Ribavirin (RBV)
Number of subjects: 14
Study: 25830404

Group type: EXPERIMENTAL
Intervention: Immediate loading (test group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional loading (control group)
Number of subjects: 34
Study: 24148799

Group type: EXPERIMENTAL
Intervention: 10 minutes of simple advice on reducing alcohol consumption
Number of subjects: 154

Group type: COMPARATOR
Intervention: No advice about drinking (Control)
Number of subjects: 154
Study: 21269302

Group type: EXPERIMENTAL
Intervention: Centrifugal blood pumps (e.g., Rotaflow, Bio-Medicus)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Roller pumps (e.g., Roller, Avecor, Sarns)
Number of subjects: 240
Study: 19675446

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 units subcutaneous on postoperative days 1 and 7)
Number of subjects: 40
Study: 16806042

Group type: EXPERIMENTAL
Intervention: Keyboard with an opening angle of 12 degrees, a gable angle of 14 degrees, and a slope of 0 degrees
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Keyboard with a gable angle of 8 degrees
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional laptop keyboard
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All 6 keyboard configurations
Number of subjects: 100
Study: 15170918

Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone pulse therapy (MPPT) - 1000 mg IV for 3 alternate days, mean interval of 76 days for one year.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oral methylprednisolone (OMP) - continuous therapy.
Number of subjects: 31
Study: 11482501

Group type: EXPERIMENTAL
Intervention: Standard filter with longer hollow fibers
Number of subjects: 24
Study: 9663183

Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine administered over a 24‐hour period every 2 to 3 weeks for 6 months.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo administered over a 24‐hour period every 2 to 3 weeks for 6 months.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine and placebo groups.
Number of subjects: 19
Study: 8310987

Group type: EXPERIMENTAL
Intervention: S (shea butter; 42% stearic acid)
Number of subjects: 15
Study: 2956297

Group type: EXPERIMENTAL
Intervention: Elase solution
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline (placebo) solution
Number of subjects: 34
Study: 29709235

Group type: EXPERIMENTAL
Intervention: MDH2008 protocol (adapted to therapeutic response to 2 cycles of chemotherapy)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: MDH2008 protocol
Number of subjects: 444
Study: 27565841

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 25555109

Group type: EXPERIMENTAL
Intervention: Strabismus surgery
Number of subjects: 97
Study: 23614743

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum extract rich in hyperforin cream
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 11
Study: 16343236

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m², Carboplatin AUC 5, Gemcitabine 800 mg/m² on day 1 and 800 mg/m² on day 8, every 3 weeks for six courses (TCG regimen)
Number of subjects: 1742

Group type: COMPARATOR
Intervention: Standard TC regimen (175 mg/m² 3 h/AUC 5 day 1 q 21 x 6)
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: TCG regimen
Number of subjects: 1742
Study: 12598738

Group type: EXPERIMENTAL
Intervention: Active phone exposure
Number of subjects: 62

Group type: COMPARATOR
Intervention: Inactive phone exposure
Number of subjects: 62

Group type: COMPARATOR
Intervention: No phone exposure
Number of subjects: 62
Study: 10633302

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 7864415

Group type: EXPERIMENTAL
Intervention: Oral meperidine (3 mg/kg) with pentobarbital (4 mg/kg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nasal ketamine (5 mg/kg) with midazolam (0.2 mg/kg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Rectal methohexital (30 mg/kg)
Number of subjects: 58
Study: 1950542

Group type: EXPERIMENTAL
Intervention: Higher doses of allergen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Allergen (any dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eosinophil cationic protein (ECP) levels
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eosinophils or ECP levels
Number of subjects: 16
Study: 7020738

Group type: EXPERIMENTAL
Intervention: Busulphan treatment
Number of subjects: 293

Group type: COMPARATOR
Intervention: Radiophosphorus therapy
Number of subjects: 293
Study: 31923924

Group type: EXPERIMENTAL
Intervention: Kinect-based physical activity program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 31242910

Group type: EXPERIMENTAL
Intervention: Scarf osteotomy with Akin osteotomy (group SA)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Scarf osteotomy without Akin osteotomy (group S)
Number of subjects: 247
Study: 28450194

Group type: EXPERIMENTAL
Intervention: Tailored self-management resources
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 25921348

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) in patients with baseline PR interval ≥180 ms
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) in patients with baseline PR interval <180 ms
Number of subjects: 87
Study: 23537492

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention with standard exercise and nutrition information plus up to five face-to-face MI sessions over 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving standard exercise and nutrition information only.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving standard information only.
Number of subjects: 0
Study: 21548660

Group type: EXPERIMENTAL
Intervention: Etamicastat 200 mg after fasting
Number of subjects: 12

Group type: COMPARATOR
Intervention: Etamicastat 200 mg after a high-fat meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Etamicastat (fasting)
Number of subjects: 12
Study: 18208875

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) therapy
Number of subjects: 46
Study: 16478838

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (80 microg/4.5 microg, two inhalations qd)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Budesonide (160 microg, two inhalations qd) plus terbutaline (0.4 mg) as needed
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 697
Study: 12790763

Group type: EXPERIMENTAL
Intervention: Dosulepine (25‐125 mg daily for 4‐8 weeks)
Number of subjects: 18
Study: 11177202

Group type: EXPERIMENTAL
Intervention: Palm oil (PO)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sunflower oil (SO)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Olive oil (OO)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-fat meals (LF)
Number of subjects: 18
Study: 9296413

Group type: EXPERIMENTAL
Intervention: Total lung collapse (TLC) plus 5 cm H2O of CPAP for 15 mins, followed by selective lobe collapse plus 5 cm H2O of CPAP (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Selective lobar collapse plus 5 cm H2O of CPAP (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Total lung collapse without CPAP (Group 3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Selective lobe collapse without CPAP (Group 4)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups (Group 1, Group 2, Group 3, Group 4)
Number of subjects: 30
Study: 8400098

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP) 0.3 microgram/kg of body weight
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study: 3755376

Group type: EXPERIMENTAL
Intervention: Intrathecal hyaluronidase
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt
Number of subjects: 9
Study: 31440909

Group type: EXPERIMENTAL
Intervention: Verbal cueing during swallowing
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-cued swallowing (unprompted)
Number of subjects: 25
Study: 29599173

Group type: EXPERIMENTAL
Intervention: Tubridge flow diverter implantation
Number of subjects: 185

Group type: COMPARATOR
Intervention: Enterprise stent-assisted coiling
Number of subjects: 185
Study: 27692669

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (SCS)
Number of subjects: 201
Study: 24111492

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 124
Study: 22423894

Group type: EXPERIMENTAL
Intervention: Neural tension technique (NTT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Random passive movements (RPM)
Number of subjects: 10
Study: 20970066

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 75
Study: 18687165

Group type: EXPERIMENTAL
Intervention: Combination therapy (valsartan 160 mg + hydrochlorothiazide 12.5 mg)
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 1313
Study: 16841677

Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue (YQHX) method
Number of subjects: 80

Group type: COMPARATOR
Intervention: Yiqi (YQ) method
Number of subjects: 80

Group type: COMPARATOR
Intervention: Huoxue (HX) method
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 80
Study: 12814457

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10642740

Group type: EXPERIMENTAL
Intervention: Diffusion imaging in MS patients with cord lesions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diffusion imaging in healthy volunteers (control)
Number of subjects: 10
Study: 8638794

Group type: EXPERIMENTAL
Intervention: C8-T2 epidural analgesia
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: C3-4 epidural analgesia
Number of subjects: 8

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 8
Study: 1762385

Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) 80 mmol K+ daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Potassium citrate/bicarbonate (K-cit/bic) 80 mmol K+ daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl)
Number of subjects: 42
Study: 6573315

Group type: EXPERIMENTAL
Intervention: Cefotetan 0.25 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefotetan 0.5 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefotetan 1.0 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefotetan 2.0 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefotetan (all doses)
Number of subjects: 10
Study: 30893392

Group type: EXPERIMENTAL
Intervention: Halobetasol propionate lotion 0.01%
Number of subjects: 430

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 430
Study: 28099220

Group type: EXPERIMENTAL
Intervention: Evacetrapib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26487393

Group type: EXPERIMENTAL
Intervention: Training as usual supplemented by change agent interactions after the training
Number of subjects: 57

Group type: COMPARATOR
Intervention: Training as usual
Number of subjects: 57
Study: 25091662

Group type: EXPERIMENTAL
Intervention: Oral monovalent rotavirus vaccine
Number of subjects: 6799

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6799
Study: 22071987

Group type: EXPERIMENTAL
Intervention: LTW fiber
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: STW fiber
Number of subjects: 120

Group type: COMPARATOR
Intervention: SF fiber
Number of subjects: 120
Study: 19659407

Group type: EXPERIMENTAL
Intervention: Telephone-based osteoporosis clinic with monthly telephone follow-up
Number of subjects: 211

Group type: COMPARATOR
Intervention: Usual care provided by primary care physician
Number of subjects: 211
Study: 17627092

Group type: EXPERIMENTAL
Intervention: Valtropin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Humatrope
Number of subjects: 147
Study: 15066665

Group type: EXPERIMENTAL
Intervention: Posaconazole (2 x 100 mg once daily for 10 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 13
Study: 11448393

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials with negative results
Number of subjects: 90
Study: 10448637

Group type: EXPERIMENTAL
Intervention: MDF treatment (5 times over 21 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDF treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 7829640

Group type: EXPERIMENTAL
Intervention: hPTH-(1-34)
Number of subjects: 10

Group type: COMPARATOR
Intervention: hPTHrP-(1-34)
Number of subjects: 10
Study: 2241185

Group type: EXPERIMENTAL
Intervention: YNK01 single administration (800 mg/body/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YNK01 5-day administration (300 mg/body/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YNK01 5-day administration (500 mg/body/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-day administration of YNK01
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse effects of YNK01
Number of subjects: 0
Study: 332370

Group type: EXPERIMENTAL
Intervention: Urgent coronary bypass surgery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intensive medical therapy
Number of subjects: 42
Study: 28002091

Group type: EXPERIMENTAL
Intervention: WFG-PRK with the VISX CustomVue Star S4 IR
Number of subjects: 71

Group type: COMPARATOR
Intervention: WFO-PRK with the Wavelight Allegretto Eye‐Q 400‐Hz laser platform
Number of subjects: 71
Study: 27739091

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (0.04 g/dl)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moderate-dose alcohol (0.065 g/dl)
Number of subjects: 120
Study: 24608203

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors
Number of subjects: 9

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 9
Study: 22938728

Group type: EXPERIMENTAL
Intervention: AgTive silver-nanoparticle-impregnated CVCs (SC)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Conventional CVCs (CC)
Number of subjects: 338
Study: 20512065

Group type: COMPARATOR
Intervention: Dynamic warm-up with no external resistance (control condition)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dynamic warm-up with weighted vest (5%, 10%, 15%, or 20% of body weight)
Number of subjects: 20
Study: 17845737

Group type: EXPERIMENTAL
Intervention: Lavender aroma
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Instructional prime (expecting aroma to inhibit relaxation)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Instructional prime (expecting aroma to facilitate relaxation)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Self-reported relaxation (changes in state anxiety)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Attitudes towards aromatherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: COMPARATOR
Intervention: No aroma
Number of subjects: 96
Study: 16181565

Group type: EXPERIMENTAL
Intervention: Combined hydrotherapy and land-based physiotherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Land-based physiotherapy only
Number of subjects: 78
Study: 11557899

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total mesorectal excision without preoperative radiotherapy
Number of subjects: 0
Study: 10204370

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) combined with components of the tricarboxylic acid cycle
Number of subjects: 208
Study: 7825044

Group type: COMPARATOR
Intervention: Iliac autograft
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Demineralized cancellous chips
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Demineralized cortical powder
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Demineralized cortical powder mixed with autograft
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Mineralized cancellous chips
Number of subjects: 144